发布时间：2025-11-05 14:06 This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2
Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2
Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4



ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2Restylane Lyft is a
=*=*=*=*=*=
当前为第1/13页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页